MP20-05 Day Case Aquablation: First Published Experience Report in Ambulatory Surgical Center (ASC)

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I (MP20)1 May 2024MP20-05 Day Case Aquablation: First Published Experience Report in Ambulatory Surgical Center (ASC) Kevin C. Zorn, Andrew P. Steinberg, Bilal Chughtai, Brian Helfand, Rahul Mehan, and Dean Elterman Kevin C. ZornKevin C. Zorn , Andrew P. SteinbergAndrew P. Steinberg , Bilal ChughtaiBilal Chughtai , Brian HelfandBrian Helfand , Rahul MehanRahul Mehan , and Dean EltermanDean Elterman View All Author Informationhttps://doi.org/10.1097/01.JU.0001008732.80104.31.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Aquablation, a novel minimally invasive technique utilizing high-velocity waterjet for precise, image-guided prostatic tissue resection, has emerged as a promising approach for BPH management. We sought to investigate the feasibility, safety and efficacy of same day discharge (SDD) after Aquablation specifically in an ASC. METHODS: A prospective cohort of men diagnosed with significant BPH underwent Aquablation at a single ASC institution between July-September 2023. Comprehensive preoperative assessments were conducted, including uroflowmetry, IPSS, and PVR. Aquablation was performed as morning cases using the AquaBeam™ Robotic System, under general anasthesia, coupled with Olympus bipolar focal bladder neck cautery and standarzied recovery irrigation pathway using a 3-way, 22F catheter with 50cc balloon inflation. Following the procedure, men were assessed for immediate postoperative outcomes, including pain levels, hematuria, and voiding efficiency. Patients meeting discharge criteria were allowed to return home on the same day. RESULTS: A total of 40 consecutive men (100%) with an average prostate size of 130 ml underwent SDD Aquablation. No transfusions or return to the OR were noted. The procedure demonstrated a significant improvement in urinary flow rates and a substantial reduction in IPSS scores at the 1 month post-operative period. Pain scores were found to be minimal, and the incidence of postoperative complications, including hematuria and urinary retention was low and comparable to previously published outcomes. Despite more meticulous focal cautery, no differences in erectile, ejaculatory or adverse outcomes were observed. CONCLUSIONS: SDD after Aquablation for BPH at an ASC appears to be a safe and effective approach, yielding favorable outcomes in terms of symptom relief and patient satisfaction. Morning procedures, more attentive cautery and streamlined patient pathways appear to be essential for SDD. Furthermore, despite electrosurgical hemostasis, ejaculatory, sexual and post-operatively pain were not compromised. Early discharge not only enhances patient experience but also optimizes healthcare resources, paving the way for a more efficient and patient-centered approach to BPH management. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e321 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kevin C. Zorn More articles by this author Andrew P. Steinberg More articles by this author Bilal Chughtai More articles by this author Brian Helfand More articles by this author Rahul Mehan More articles by this author Dean Elterman More articles by this author Expand All Advertisement PDF downloadLoading ...